Last reviewed · How we verify
NCT00342810
Analyses of Existing Framingham Data
trial in Eye Diseases in 6,061 participants. Completed in 25 April 2018.
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6,061 |
| Start date | 25 June 2003 |
| Estimated completion | 25 April 2018 |
| Sites | 1 location across United States |
Conditions studied
- Eye Diseases — all drugs for Eye Diseases →
Sponsor
National Eye Institute (NEI)
Who can join
Adults 30 to 100, any sex, with Eye Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Since 1948, the Framingham Study has examined a group of men and women every two years for the primary purpose of studying the incidence and prevalence of cardiovascular disease and its risk factors. In 1971 the Framingham Study began a study of the offspring of the original group, including data collection on blood pressure, cigarette smoking, weight, and other factors that are of interest to studies of eye disease. Researchers gave eye exams to some of the original group and to the offspring group. Data from these eye exams have been used to examine risk factors for cataracts, diabetic retinopathy, myopia, and glaucoma. The purpose of this study is to use the previously collected data for continued research on eye-related disorders. No new eye examinations will be conducted. ...
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00342810
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Eye Diseases
Currently open trials in the same condition.
- NCT07322302 — RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) · NA · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT06812845 — Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University Hospital · recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00342810 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 17 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00342810.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing